Literature DB >> 14667787

AIDS in Africa: the impact of coinfections on the pathogenesis of HIV-1 infection.

S D Lawn1.   

Abstract

The intimate relationship between the HIV-1 life-cycle and the activation state of cells supporting viral replication results in a dynamic interaction between coinfections and HIV-1 replication in dually infected people. The immunologic impact of recurrent coinfections has the potential to increase viral replication, viral genotypic heterogeneity and CD4 T lymphocyte loss, leading to accelerated decline in immune function, reduced survival and increased HIV-1 transmission risk. These effects may play a particularly significant role in the HIV-1 epidemic in sub-Saharan Africa. The mechanisms underlying these effects on virus-host dynamics are reviewed and data describing the impact of tuberculosis, malaria, schistosomiasis and genital ulceration on HIV-1 infection are presented.

Entities:  

Mesh:

Year:  2004        PMID: 14667787     DOI: 10.1016/j.jinf.2003.09.001

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  34 in total

1.  HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells.

Authors:  Sonja I Gringhuis; Michiel van der Vlist; Linda M van den Berg; Jeroen den Dunnen; Manja Litjens; Teunis B H Geijtenbeek
Journal:  Nat Immunol       Date:  2010-04-04       Impact factor: 25.606

2.  Computational investigation of the anti-HIV activity of Chinese medicinal formula Three-Huang Powder.

Authors:  Jack Z Hu; Li Bai; Da-Gang Chen; Qi-Tai Xu; William M Southerland
Journal:  Interdiscip Sci       Date:  2010-05-01       Impact factor: 2.233

3.  Supernatants from oral epithelial cells and gingival fibroblasts modulate human immunodeficiency virus type 1 promoter activation induced by periodontopathogens in monocytes/macrophages.

Authors:  O A González; J L Ebersole; C B Huang
Journal:  Mol Oral Microbiol       Date:  2010-04       Impact factor: 3.563

4.  Change over time of mortality predictors after HAART initiation in a Senegalese cohort.

Authors:  Pierre De Beaudrap; Jean-François Etard; René Ecochard; Assane Diouf; Allé Baba Dieng; Vannina Cilote; Ibrahima Ndiaye; Ndèye Fatou Ngom Guèye; Pape Mandoumbé Guèye; Papa Salif Sow; Souleymane Mboup; Ibra Ndoye; Eric Delaporte
Journal:  Eur J Epidemiol       Date:  2008-01-16       Impact factor: 8.082

Review 5.  Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression.

Authors:  Kayvon Modjarrad; Eric Chamot; Sten H Vermund
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

Review 6.  The role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis.

Authors:  Ruanne V Barnabas; Emily L Webb; Helen A Weiss; Judith N Wasserheit
Journal:  AIDS       Date:  2011-08-24       Impact factor: 4.177

7.  Coinfection Dynamics of Two Diseases in a Single Host Population.

Authors:  Daozhou Gao; Travis C Porco; Shigui Ruan
Journal:  J Math Anal Appl       Date:  2016-04-19       Impact factor: 1.583

8.  Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa.

Authors:  Sabine M Hermans; Agnes N Kiragga; Petra Schaefer; Andrew Kambugu; Andy I M Hoepelman; Yukari C Manabe
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

Review 9.  Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs.

Authors:  Simi Gunaseelan; Krishnan Gunaseelan; Manjeet Deshmukh; Xiaoping Zhang; Patrick J Sinko
Journal:  Adv Drug Deliv Rev       Date:  2009-11-24       Impact factor: 15.470

10.  Downregulation of MIP-1alpha/CCL3 with praziquantel treatment in Schistosoma haematobium and HIV-1 co-infected individuals in a rural community in Zimbabwe.

Authors:  Rbl Zinyama-Gutsire; E Gomo; P Kallestrup; C Erikstrup; H Ullum; A E Butterworth; S Munyati; T Mduluza
Journal:  BMC Infect Dis       Date:  2009-10-23       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.